Acumen Pharmaceuticals
ABOS
67 hedge funds and large institutions have $148M invested in Acumen Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 28 increasing their positions, 9 reducing their positions, and 18 closing their positions.
211% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 9
11% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 18
2% more funds holding
Funds holding: 66 → 67 (+1)
8.21% less ownership
Funds ownership: 74.63% → 66.42% (-8.2%)
18% less capital invested
Capital invested by funds: $179M → $148M (-$31.5M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
82% less call options, than puts
Call options by funds: $810K | Put options by funds: $4.57M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$1.74M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$1.54M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$956K |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$733K |
| 5 |
Man Group
London,
United Kingdom
|
+$429K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$10.4M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$9.16M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.46M |
| 4 |
ACM
Altium Capital Management
New York
|
-$2.7M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$1.52M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
UOC
76
UBS O'Connor
Chicago,
Illinois
| – | -$289K | -69,538 | Closed |
|
77
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
| – | -$167K | -40,000 | Closed |
|
78
Marshall Wace
London,
United Kingdom
| – | -$106K | -25,492 | Closed |
|
79
Verition Fund Management
Greenwich,
Connecticut
| – | -$97.5K | -23,500 | Closed |
|
|
PA
80
Pinnacle Associates
New York
| – | -$74.8K | -18,020 | Closed |
|
|
PWMAG
81
Pinnacle Wealth Management Advisory Group
Red Bank,
New Jersey
| – | -$74.8K | -18,020 | Closed |
|
|
XT
82
XTX Topco
George Town,
Cayman Islands
| – | -$68.6K | -16,538 | Closed |
|
|
CUAMC
83
China Universal Asset Management Company
Shanghai,
China
| – | -$6.15K | -1,481 | Closed |
|
84
Fidelity Investments
Boston,
Massachusetts
| – | -$2.73K | -657 | Closed |
|
85
Daiwa Securities Group
Tokyo,
Japan
| – | -$1K | -165 | Closed |
|
ABOS Hedge Fund Activity: Q4 2023 in Review
67 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q4 2023, worth a combined $148M — down 18% from $179M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ABOS positions and 18 closed out — a net gain of 2 holders — while 28 added to existing stakes and 9 trimmed.
The largest buyer was Jane Street, adding an estimated $1.74M. The largest seller was Deep Track Capital, exiting entirely with an estimated $10.4M sold.
- 67 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q4 2023, up from 66 in Q3 2023.
- Funds reported $148M of Acumen Pharmaceuticals stock for Q4 2023, down 18% quarter-over-quarter.
- 20 funds opened new Acumen Pharmaceuticals positions in Q4 2023 and 18 closed out, a net change of +2 holders.
- The largest Acumen Pharmaceuticals buyer in Q4 2023 was Jane Street, an estimated $1.74M added.
- The largest Acumen Pharmaceuticals seller in Q4 2023 was Deep Track Capital, an estimated $10.4M sold.
Based on aggregated 13F filings for Q4 2023.